Ketryx, the agentic continuous compliance platform for safety-critical product development, announced today that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company's Series B financing, signaling strong industry confidence in Ketryx's mission to accelerate product development while maintaining regulatory compliance.
Ketryx helps companies in safety-critical industries, including medical devices, pharmaceuticals, and robotics, accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale in the tools teams already use. The platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles without disrupting workflows. Ketryx AI Agents reduce manual work by up to 90 percent and help teams identify and close compliance gaps, improving both speed and quality across the product lifecycle.
Hawkins brings decades of leadership experience in the medical technology sector. As former Chairman and CEO of Medtronic, he oversaw significant growth and innovation in medical devices. His expertise will be invaluable as Ketryx expands its footprint in life sciences and other safety-critical industries. The company is trusted by four of the world's top five medical device manufacturers, highlighting its relevance in a sector where compliance is paramount.
The announcement comes at a time when the life sciences industry faces increasing pressure to adopt AI and digital tools while navigating complex regulatory requirements. Ketryx's platform addresses the bottleneck of manual compliance processes, enabling faster innovation without compromising safety or quality. By automating documentation and traceability, the platform allows teams to focus on product development rather than administrative tasks.
For more information about Ketryx and its platform, visit www.ketryx.com.
